Product “Vardenafil Hydrochloride Tablets” obtained registration certificate
August 2, 2025
Source: drugdu
82
Lukang Pharmaceutical(SH 600789, closing price: 10.5 yuan) issued an announcement on the evening of July 31st, stating that recently, Shandong Lu'an Pharmaceutical Co., Ltd.'s holding subsidiary Shandong Lu'an Pharmaceutical Group Saite Co., Ltd. received the "Drug Registration Certificate" for Vardenafil Hydrochloride Tablets issued by the State Food and Drug Administration. This drug is a generic drug approved in accordance with the new registration classification 4 and is deemed to have passed the generic drug quality and efficacy consistency evaluation.
From January to December 2024, the operating income structure of Lu'an Pharmaceutical was as follows: human antibiotics accounted for 54.29%, veterinary antibiotics accounted for 39.72%, others accounted for 4.89%, and other businesses accounted for 1.1%.
Source：https://finance.eastmoney.com/a/202507313472779816.html
By editor
Copyright©2025 Ddu. All rights reserved.
Read more on
- The application for marketing authorization of trivalent influenza virus split vaccine has been accepted October 8, 2025
- Walvax Biopharma’s vaccine receives Jordanian Drug Registration Certificate, marking a key step forward in its Middle East market expansion. October 8, 2025
- Zhifei Bio’s independent product, influenza virus split vaccine, has obtained a drug registration certificate October 8, 2025
- Antihypertensive and lipid-lowering drugs show efficacy against steatotic liver disease October 7, 2025
- Large-scale analysis offers insights into sporadic nature of chikungunya virus outbreaks October 7, 2025
your submission has already been received.
OK
Subscribe
Please enter a valid Email address！
Submit
The most relevant industry news & insight will be sent to you every two weeks.
